vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $208.0M, roughly 1.6× VIRTUS INVESTMENT PARTNERS, INC.). VIRTUS INVESTMENT PARTNERS, INC. runs the higher net margin — 16.3% vs 13.2%, a 3.1% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -10.9%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-74.1M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -3.2%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
HAE vs VRTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $208.0M |
| Net Profit | $44.7M | $33.9M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 19.1% |
| Net Margin | 13.2% | 16.3% |
| Revenue YoY | -2.7% | -10.9% |
| Net Profit YoY | 19.3% | -14.2% |
| EPS (diluted) | $0.95 | $5.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $208.0M | ||
| Q3 25 | $327.3M | $216.4M | ||
| Q2 25 | $321.4M | $210.5M | ||
| Q1 25 | $330.6M | $217.9M | ||
| Q4 24 | $348.5M | $233.5M | ||
| Q3 24 | $345.5M | $227.0M | ||
| Q2 24 | $336.2M | $224.4M | ||
| Q1 24 | — | $222.0M |
| Q4 25 | $44.7M | $33.9M | ||
| Q3 25 | $38.7M | $31.3M | ||
| Q2 25 | $34.0M | $42.7M | ||
| Q1 25 | $58.0M | $28.1M | ||
| Q4 24 | $37.5M | $39.5M | ||
| Q3 24 | $33.8M | $49.1M | ||
| Q2 24 | $38.4M | $26.0M | ||
| Q1 24 | — | $37.9M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 19.1% | ||
| Q3 25 | 17.9% | 21.7% | ||
| Q2 25 | 16.8% | 21.5% | ||
| Q1 25 | 21.6% | 16.8% | ||
| Q4 24 | 16.9% | 21.7% | ||
| Q3 24 | 15.0% | 24.3% | ||
| Q2 24 | 11.8% | 19.7% | ||
| Q1 24 | — | 14.5% |
| Q4 25 | 13.2% | 16.3% | ||
| Q3 25 | 11.8% | 14.5% | ||
| Q2 25 | 10.6% | 20.3% | ||
| Q1 25 | 17.5% | 12.9% | ||
| Q4 24 | 10.8% | 16.9% | ||
| Q3 24 | 9.8% | 21.6% | ||
| Q2 24 | 11.4% | 11.6% | ||
| Q1 24 | — | 17.1% |
| Q4 25 | $0.95 | $5.15 | ||
| Q3 25 | $0.81 | $4.65 | ||
| Q2 25 | $0.70 | $6.12 | ||
| Q1 25 | $1.17 | $4.05 | ||
| Q4 24 | $0.74 | $4.65 | ||
| Q3 24 | $0.66 | $5.71 | ||
| Q2 24 | $0.74 | $2.43 | ||
| Q1 24 | — | $4.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | — |
| Total DebtLower is stronger | $1.2B | $390.0M |
| Stockholders' EquityBook value | $911.5M | $934.0M |
| Total Assets | $2.5B | $4.3B |
| Debt / EquityLower = less leverage | 1.34× | 0.42× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | — | ||
| Q3 25 | $296.4M | — | ||
| Q2 25 | $292.9M | — | ||
| Q1 25 | $306.8M | — | ||
| Q4 24 | $320.8M | — | ||
| Q3 24 | $299.3M | — | ||
| Q2 24 | $344.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $390.0M | ||
| Q3 25 | $1.2B | $390.6M | ||
| Q2 25 | $1.2B | $231.3M | ||
| Q1 25 | $1.2B | $231.7M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $237.5M | ||
| Q2 24 | — | $247.6M | ||
| Q1 24 | — | $253.0M |
| Q4 25 | $911.5M | $934.0M | ||
| Q3 25 | $849.2M | $918.7M | ||
| Q2 25 | $882.3M | $896.4M | ||
| Q1 25 | $820.8M | $893.7M | ||
| Q4 24 | $906.9M | $897.5M | ||
| Q3 24 | $878.9M | $889.0M | ||
| Q2 24 | $905.4M | $868.7M | ||
| Q1 24 | — | $871.7M |
| Q4 25 | $2.5B | $4.3B | ||
| Q3 25 | $2.4B | $3.9B | ||
| Q2 25 | $2.5B | $3.7B | ||
| Q1 25 | $2.5B | $3.7B | ||
| Q4 24 | $2.5B | $4.0B | ||
| Q3 24 | $2.5B | $3.6B | ||
| Q2 24 | $2.5B | $3.6B | ||
| Q1 24 | — | $3.5B |
| Q4 25 | 1.34× | 0.42× | ||
| Q3 25 | 1.44× | 0.43× | ||
| Q2 25 | 1.39× | 0.26× | ||
| Q1 25 | 1.49× | 0.26× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $-67.2M |
| Free Cash FlowOCF − Capex | $87.2M | $-74.1M |
| FCF MarginFCF / Revenue | 25.7% | -35.6% |
| Capex IntensityCapex / Revenue | 1.9% | 3.3% |
| Cash ConversionOCF / Net Profit | 2.09× | -1.99× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $100.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $-67.2M | ||
| Q3 25 | $111.3M | $108.3M | ||
| Q2 25 | $17.4M | $75.8M | ||
| Q1 25 | $116.6M | $-3.8M | ||
| Q4 24 | $43.8M | $1.8M | ||
| Q3 24 | $48.8M | $69.1M | ||
| Q2 24 | $-27.4M | $70.0M | ||
| Q1 24 | — | $-34.5M |
| Q4 25 | $87.2M | $-74.1M | ||
| Q3 25 | $106.3M | $106.9M | ||
| Q2 25 | $13.6M | $74.2M | ||
| Q1 25 | $100.9M | $-6.8M | ||
| Q4 24 | $35.2M | $-3.8M | ||
| Q3 24 | $39.4M | $68.7M | ||
| Q2 24 | $-33.1M | $68.6M | ||
| Q1 24 | — | $-36.5M |
| Q4 25 | 25.7% | -35.6% | ||
| Q3 25 | 32.5% | 49.4% | ||
| Q2 25 | 4.2% | 35.2% | ||
| Q1 25 | 30.5% | -3.1% | ||
| Q4 24 | 10.1% | -1.6% | ||
| Q3 24 | 11.4% | 30.3% | ||
| Q2 24 | -9.8% | 30.6% | ||
| Q1 24 | — | -16.4% |
| Q4 25 | 1.9% | 3.3% | ||
| Q3 25 | 1.5% | 0.7% | ||
| Q2 25 | 1.2% | 0.7% | ||
| Q1 25 | 4.7% | 1.4% | ||
| Q4 24 | 2.5% | 2.4% | ||
| Q3 24 | 2.7% | 0.2% | ||
| Q2 24 | 1.7% | 0.6% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | 2.09× | -1.99× | ||
| Q3 25 | 2.88× | 3.45× | ||
| Q2 25 | 0.51× | 1.77× | ||
| Q1 25 | 2.01× | -0.13× | ||
| Q4 24 | 1.17× | 0.04× | ||
| Q3 24 | 1.44× | 1.41× | ||
| Q2 24 | -0.71× | 2.69× | ||
| Q1 24 | — | -0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
VRTS
| Open End Funds | $68.9M | 33% |
| Retail Separate Accounts | $51.3M | 25% |
| Institutional Accounts | $39.6M | 19% |
| Administration And Shareholder Service Fees | $18.4M | 9% |
| Closed End Funds | $15.9M | 8% |
| Distribution And Service Fees | $12.3M | 6% |
